61 results
8-K
EX-99.1
GLYC
GlycoMimetics Inc
27 Mar 24
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023
9:00am
costs due to the completion of engineering and validation batches for uproleselan, partially offset by the Phase 1 clinical trial of GMI-1687.
G … to $19.1 million in the prior year. The overall increase was due to higher personnel-related expenses, offset in part by a decrease in external
8-K
EX-99.1
GLYC
GlycoMimetics Inc
28 Apr 22
GlycoMimetics Reports Highlights and Financial Results
8:30am
AML as patient enrollment ended in November 2021. The decrease was partially offset by higher manufacturing expenses for uproleselan validation
8-K
EX-99.1
GLYC
GlycoMimetics Inc
3 Nov 23
GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023
8:35am
related to the Phase 1a trial of GMI-1687 in healthy adult volunteers, which was initiated in August 2023; the increase was partially offset
8-K
EX-99.1
GLYC
GlycoMimetics Inc
9 Aug 18
Glycomimetics Reports Second Quarter 2018 Results and Highlights Recent Company Achievements
4:10pm
by or in collaboration with third parties. This increase was offset in part by a decrease in clinical trial expenses as patient enrollment for our Phase
8-K
EX-99.1
GLYC
GlycoMimetics Inc
3 Mar 22
GlycoMimetics Reports Highlights and Financial Results
8:45am
in the prior year. These increases were due to higher recruiting, consulting and legal expenses incurred in 2021 offset by lower personnel-related expenses due
8-K
EX-99.1
1afs7 daz4f
1 May 20
Glycomimetics Reports Operational Highlights and Financial Results for
9:00am
8-K
EX-99.1
jfwx6cyz7qcjp
2 Mar 21
Glycomimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2020
4:16pm
8-K
EX-99.1
rploy
6 Nov 20
Glycomimetics Reports Highlights and Financial Results for
9:29am
8-K
EX-99.1
wscbj2snflrhn
31 Jul 20
Glycomimetics Reports Highlights and Financial Results for
9:09am